- Home
- GENK vs AEON Comparison
GENK vs AEON Comparison
Compare GENK & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.42
HOLD
Current Price
$1.21
Company Overview
Basic Information| Metric | GENK | AEON |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1M | 13.2M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | GENK | AEON |
|---|---|---|
| Price | $2.42 | $1.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $5.67 | ★ $7.20 |
| AVG Volume (30 Days) | 66.6K | ★ 209.2K |
| Earning Date | 03-05-2026 | 11-14-2025 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $217,449,000.00 | N/A |
| Revenue This Year | $8.46 | N/A |
| Revenue Next Year | $8.17 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.36 | N/A |
| 52 Week Low | $2.10 | $0.38 |
| 52 Week High | $7.41 | $11.02 |
Technical Indicators
Market Signals| Indicator | GENK | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 63.88 |
| Support Level | $2.43 | $1.02 |
| Resistance Level | $2.60 | $1.18 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 37.50 | 57.06 |
Price Performance
Historical Comparison GENK
AEON
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.